Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner


rss_Pharma.jpg...see all
World Diabetes Market Analysis 2010-2025

World Diabetes Market Analysis 2010-2025

  • Publication date: 03/03/2010
  • Number of Pages: 152
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

– how will this market develop, with rising disease prevalence in many countries?

In 2009, the diabetes treatment market generated worldwide sales of over $25 billion, with strong growth from the previous year. The incidence and prevalence of diabetes mellitus are on the rise worldwide, in line with lifestyle changes and ageing populations. In particular, the increasing prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities in developed nations and some developing countries. The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing heavily in prevention and treatment of this serious - but controllable - disorder.

As our new report – World Diabetes Market Analysis 2010-2025 – shows, the diabetes market is one of the most important sectors in the pharmaceutical industry. All segments of the diabetes therapy market have been expanding, but which will grow fastest in years to come? What are the main therapeutic and commercial trends to watch? How will the principal national markets perform from 2010 to 2025? What will happen to the current leading products/therapies? How does diabetes overlap with obesity? This report covers those and other crucial questions, providing the information that you need.

Success in the diabetes treatment market from 2010 onwards will be characterised by the launch of products with superior performance. This report shows how emerging technologies that increase clinical effectiveness, tolerability and ease of use will be important therapeutically and commercially.

Detailed analysis of the global diabetes market

World Diabetes Market Analysis 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 75 tables and figures included, as well as three full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy World Diabetes Market Analysis 2010-2025

This report gives you the following benefits in particular:
• You will receive a comprehensive analysis of the prospects for anti-diabetes drugs from 2010 to 2025, including predicted revenues, growth rates and other metrics for leading products
• You will receive an overall forecast for the global diabetes treatment market from 2010 to 2025, as well as those for main drug classes, with comprehensive discussions and other supporting information
• You will find out where the market is heading – both technologically and commercially – from 2010 onwards
• You will receive sales forecasts for the leading national markets from 2010 to 2025 (US, Japan, UK, Germany, France, Spain, Italy, Brazil, China and India)
• You will identify key R&D pipeline developments and up-and-coming products
• You will discover the drivers, restraints, competition and opportunities influencing the diabetic treatment sector, including insulins and oral anti-diabetics classes
• You will investigate under-met needs in that sector, with both therapeutic requirements and commercial opportunities discussed
• You will discover expert views from our survey, including full interview transcripts.
• You can obtain this report today

This report is essential reading for everybody interested in the diabetes treatments sector. With rising disease prevalence, expanding patient populations and unmet needs, this therapeutic area holds significant potential for further revenue growth. Our new study reveals prospects for both existing competitors and potential market entrants from the present onwards. You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary
1.1 The Diabetes Market Trajectory
1.1.1 Visiongain's Prediction for Total Diabetes Sales in 2025
1.1.2 Diabetes is Spreading at an Epidemic Rate: The Need for Pharmaceuticals is Growing
1.1.3 Diabetes Care Works: The Market will Expand Significantly
1.1.4 Awareness, Advocacy and Government Spending Aimed at Diabetes are all Expanding
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Diabetes and its Treatment
2.1 What is Diabetes Mellitus?
2.1.1 Symptoms of Diabetes
2.1.2 Type 1 Diabetes
2.1.3 Type 2 Diabetes
2.1.4 Gestational Diabetes
2.1.5 Other Types of Diabetes
2.1.6 "Pre-Diabetes": Impaired Glucose Tolerance (IGT) and Metabolic Syndrome
2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye, and Nerve Damage
2.2.1 Heart Problems
2.2.2 Kidney Damage
2.2.3 Blindness
2.2.4 Neuropathy
2.2.5 Amputation
2.2.6 Ketoacidosis, Coma, and Death
2.3 Obesity: The Major Diabetes Risk Factor
2.4 Other Risk Factors: Age, Genetics, Race
2.4.1 Type 2 Diabetes Risk Increases with Age
2.4.2 Obesity Increases Chances of Type 2 Diabetes
2.4.3 Genetic Factors
2.4.4 Type 1 Diabetes: Genetics vs. Environment
2.4.5 Family History
2.4.6 Ethnicity
2.5 Diagnosis: Guidelines are Subject to Change
2.6 Prevalence: Diabetes Rates are Rising Epidemically
2.7 The Economic Costs of Diabetes: $58 billion in the US
2.8 Treatments
2.8.1 Insulin: a Central Therapeutic Product
2.8.2 Medications
2.8.3 More Novel Therapies? A New Discovery about how Insulin Works May Lead to New Drugs
2.9 Diabetes Treatment Noncompliance Rates 25% to 90%

3. The World Diabetes Drug Market, 2010-2025
3.1 The World Diabetes Drug Market in 2009
3.1.1 Human Insulins & Analogues had Largest Market Share in 2009
3.1.2 Top Twenty Anti-Diabetic Brands, 2009
3.2 The World Diabetes Drug Market Forecast, 2010-2025
3.3 Anti-Diabetic Pharmaceutical Therapeutic Category Sales Forecasts, 2010-2025
3.3.1 Two Therapeutic Categories will Power Growth from 2010-2016
3.3.2 Human Insulins and Analogues will Continue to Drive Growth from 2017-2025

4. Human Insulins and Analogues: Market Prospects, 2010-2025
4.1 Leading Human Insulins and Analogues
4.1.1 Lantus – Commercial Prospects
4.1.2 Novorapid – Commercial Prospects
4.1.3 Humalog – Commercial Prospects
4.1.4 Novomix – Commercial Prospects
4.1.5 Levemir – Commercial Prospects
4.1.6 Actraphane HM – Commercial Prospects

5. Other Anti-Diabetic Agents: Market Prospects, 2010-2025
5.1 Leading Oral Anti-Diabetic Products
5.1.1 Actos – Commercial Prospects
5.1.2 Avandia: How will Sales Fare After 2013?
5.1.3 Avandamet – Commercial Prospects
5.1.4 Januvia – Commercial Prospects
5.2 Byetta/Exenatide LAR: Potentially Revolutionary Non-Insulin Injection Blockbuster
5.2.1 Byetta's Strengths
5.2.2 Restraints on Byetta

6. Drivers and Restraints in the Diabetes Drug Market
6.1 Strengths: Diabetes is Increasing, and Diabetes Drugs Work
6.1.1 Diabetes is Chronic
6.1.2 Younger Patients, More-Comprehensive Diagnoses
6.1.3 Prevention is Inadequate
6.1.4 Drugs Often Used in Combination
6.2 Weaknesses
6.2.1 Diagnostic Inadequacies
6.2.2 Developing Countries Cannot Afford Many Drugs
6.2.3 Noncompliance Rates up to 65%
6.3 Opportunities
6.3.1 Increasing Prevalence of Diabetes and Unhealthy Lifestyles
6.3.2 The Greying of the World Population
6.3.3 Obesity: A Major Contributing Factor for Type 2 Diabetes
6.3.4 Expanding Markets: India and China
6.3.5 Changing Guidelines for Defining Diabetes
6.3.6 Techniques for Increasing Patient Compliance
6.3.7 Novel Drugs, Novel Delivery Methods
6.4 Threats
6.4.1 The Most-Significant Threat: Changes in Drug Approval Guidelines
6.4.2 Changing FDA Guidelines for New Drug Approvals
6.4.3 Generic Erosion of Branded Drug Sales
6.4.4 Vaccine to Prevent Type 1 Diabetes?
6.4.5 Diabetes Drugs' Side Effects

7. Antidiabetic Drugs: Leading Country Markets, 2010-2025
7.1 Leading Anti-Diabetic Pharmaceutical Country Markets, 2009
7.2 Leading Developed Country Anti-Diabetic Pharmaceutical Markets, 2010-2025
7.2.1 The US Anti-Diabetic Pharmaceutical Market
7.2.2 The Japanese Anti-Diabetic Pharmaceutical Market
7.2.3 European Diabetes Pharmaceutical Markets
7.3 Emerging Economy Anti-Diabetic Pharmaceutical Market Forecasts, 2010-2025
7.3.1 Anti-Diabetic Pharmaceuticals are Making the Leap to Developing Countries
7.3.2 The Chinese Anti-Diabetic Pharmaceutical Market
7.3.3 The Indian Anti-Diabetic Pharmaceutical Market

8. The R&D Pipeline for Diabetes Treatments
8.1 The Anti-Diabetic Drugs Pharmaceutical Pipeline
8.2 The Human Insulins and Analogues Pipeline
8.2.1 Technosphere Insulin (Mankind)
8.2.2 VIAject/VIAdel (Biodel)
8.2.3 CKD 401(Chong Kun Dang)
8.2.4 BHT 3021/RG 7426 (Bayhill Therapeutics/Genentech)
8.2.5 Nasulin/CPE-215 (CPEX Pharmaceuticals)
8.2.6 Capsulin (Diabetology)
8.2.7 ORMD 0801 (Oramed)
8.2.8 TPM 02/Insulin (Phosphagenics)
8.2.9 IN 105 (Biocon)
8.2.10 NN 1250 (Novo Nordisk)
8.2.11 NN 5401 (Novo Nordisk)
8.2.12 SBS 1000 (SemBioSys)
8.3 The Glitazone Anti-Diabetics Pipeline
8.3.1 ACTOplus met XR (Takeda)
8.3.2 Balaglitazone/DRF 2593 (Dr Reddy's/Nordic Bioscience)
8.3.3 MK 0431C (Merck & Co)
8.3.4 MSDC 0160 (Metabolic Solutions Development)
8.3.5 Lobeglitazone/CKD 501 (Chong Kun Dang)
8.4 DPP-IV Inhibitor Anti-Diabetics Pipeline
8.4.1 SYR 322 (Takeda)
8.4.2 Alogliptin (Takeda)
8.4.3 Linagliptin/BI 1356 BS (Boehringer Ingelheim)
8.4.4 Dutogliptin/PHX 1149 (Phenomix)
8.4.5 LC 15 0444 (LG Life Sciences)
8.4.6 Saxagliptin and Metformin Combination
8.4.7 MK 0431C (Merck & Co)
8.4.8 SK 0403 (Sanwa Kagaku/ Kowa/ Choongwae)
8.4.9 Teneligliptin/MP 513 (Mitsubishi Tanabe Pharma)
8.4.10 ALS 20426/AMG 222 (Amgen)
8.4.11 Carmegliptin/R 1579 (Roche)
8.4.12 KRP 104 (Kyorin)
8.4.13 Melogliptin/GRC 8200 (Glenmark)
8.4.14 SYR 472 (Takeda)
8.4.15 TA 6666 (Mitsubishi Tanabe Pharma)
8.5 Sulphonylurea and Biguanide Anti-Diabetics Pipeline
8.5.1 NCT00660907/Dapagliflozin + Metformin Combination (AstraZeneca)
8.5.2 Metformin XL (Flamel Technologies)
8.5.3 Metcontrol (Generex Biotechnology)
8.6 Alpha-glucosidase Inhibitor Anti-Diabetics Pipeline
8.6.1 KMV 0207 (Kissei/Takeda)
8.6.2 PharmaLinks Compounds (University of Strathclyde)
8.7 Miscellaneous Class of Anti-Diabetic Drugs in the R&D Pipeline
8.7.1 Byetta LAR/AC 2993 LAR (Amylin/Alkermes/Eli Lilly)
8.7.2 Albiglutide/GSK 716155 (GlaxoSmithKline)
8.7.3 Lixisenatide/ZP 10/AVE 0010 (sanofi-aventis)
8.7.4 LY 2189265 (Eli Lilly)
8.7.5 Taspoglutide/ BIM 51077 (Roche)
8.7.6 ITCA 650 (Intarcia)
8.7.7 Gosogliptin/PF 734200 (Pfizer)
8 7.8 Semaglutide/NN 9535 (Novo Nordisk)
8.7.9 Bromocriptine/Cycloset (VeroScience/ S2 Therapeutics)
8.7.10 SF 1019/R-1818 (Argyll Biotechnologies)
8.7.11 Arhalofenate/MBX 102 (Metabolex and Ortho-McNeil)
8.7.12 Canagliflozin/TA 7284 (Mitsubishi Tanabe Pharma/ Johnson & Johnson)
8.7.13 Dapagliflozin (Bristol-Myers Squibb)
8.7.14 DiaPep277 (Andromeda/ DeveloGen)
8.7.15 Mirabegron/YM 178 (Astellas)
8.7.16 Otelixizumab/TRX 4/ChAglyCD3 (GlaxoSmithKline/Tolerx/BTG)
8.7.17 Teplizumab/MGA 031 (MacroGenics/Eli Lilly)
8.7.18 DIAMYD/GAD65 (Diamyd Medical)

9. Expert Views from Key Opinion Leaders
9.1 Prof. R. Keith Campbell, Pharm.B., MBA, CDE Distinguished Professor in Diabetes Care, Department of Pharmacotherapy, College of Pharmacy, Washington State University, WA, US
9.1.1 Key Unmet Needs
9.1.2 About Research and Development
9.1.3 Problems with the Current Use of Anti-Diabetic Treatments
9.1.4 Challenges in the Development of Anti-Diabetic Drugs
9.1.5 Complexities Involved in Developing New Anti-Diabetic Drugs
9.1.6 Technologies and Strategies for Discovery of New Anti-Diabetic Agents
9.1.7 Growth Opportunities in Diabetes Market
9.1.8 Challenges Facing the Diabetes Pharmaceutical Industry
9.1.9 Main Regions Offering Growth Potential Worldwide
9.1.10 Pipeline Developments from a Physician's Perspective
9.1.11 Prospects of Replacing Current Drugs and Treatments
9.2 Interview with Dr Fred Levine, M.D., Ph.D. Professor, Burnham Institute for Medical Research; Director, Sanford Children's Health Research Center, La Jolla, California, US
9.2.1 On Alternative Delivery Methods
9.2.2 On Cardiovascular Problems Associated with Oral Anti-Diabetics
9.2.3 On Obesity and Diabetes
9.2.4 On Byetta
9.2.5 On Stem Cell Therapy/Cure
9.3 Interview with Björn Tyrberg, PhD., Associate Professor, Metabolic Signaling & Disease, Diabetes and Obesity Research Center, Burnham Institute for Medical Research, La Jolla, CA, US
9.3.1 On Diet and Diabetes
9.3.2 On The Link Between Obesity and Diabetes
9.3.3 On Byetta and Liraglutide

10. Conclusions: Diabetes is a Growth Market with Significant Opportunities
10.1 Diabetes Increasing Worldwide: 2-14% Prevalence Rate
10.2 World Diabetes Market: A Growing Opportunity
10.3 Oral Anti-Diabetics Sales vs. Insulins Sales

List of Tables
Table 2.1 Diabetes Numbers (in Millions), by WHO Region, 2000 & 2030
Table 2.2 Secondary Costs of Diabetes in the US, 2007
Table 2.3 Total Costs of Diabetes to Africa: $4.2 Billion, 2007
Table 2.4 Diabetes World Market Sales, 2009
Table 2.5 Insulin Types by Onset Rate, 2010
Table 2.6 Alternative Delivery Methods in the R&D Pipeline by Type and Development Stage, 2010
Table 2.7 Anti-Diabetic Drugs by Class, 2010
Table 3.1 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009
Table 3.2 Top Twenty Diabetes Pharmaceutical Brands, 2009
Table 3.3 World Diabetes Pharmaceutical Market Sales Forecast, 2010-2016
Table 3.4 World Diabetes Pharmaceutical Market Sales Forecast, 2017-2025
Table 3.5 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts, 2010-2016
Table 3.6 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts, 2017-2025
Table 4.1 Lantus Sales Forecast, 2010-2016
Table 4.2 Lantus Sales Forecast, 2017-2025
Table 4.3 Novorapid Sales Forecast, 2010-2016
Table 4.4 Novorapid Sales Forecast, 2017-2025
Table 4.5 Humalog Sales Forecast, 2010-2016
Table 4.6 Humalog Sales Forecast, 2017-2025
Table 4.7 Novomix Sales Forecast, 2010-2016
Table 4.8 Novomix Sales Forecast, 2017-2025
Table 4.9 Levemir Sales Forecast, 2010-2016
Table 4.10 Levemir Sales Forecast, 2017-2025
Table 4.11 Actraphane HM Sales Forecast, 2010-2016
Table 4.12 Actraphane HM Sales Forecast, 2017-2025
Table 5.1 Actos Sales Forecast, 2010-2016
Table 5.2 Actos Sales Forecast, 2017-2025
Table 5.3 Avandia Sales Forecast, 2010-2016
Table 5.4 Avandia Sales Forecast, 2017-2025
Table 5.5 Avandamet Sales Forecast, 2010-2016
Table 5.6 Avandamet Sales Forecast, 2017-2025
Table 5.7 Junuvia Sales Forecast, 2010-2016
Table 5.8 Junuvia Sales Forecast, 2017-2025
Table 5.9 Byetta Sales Forecast, 2010-2016
Table 5.10 Byetta Sales Forecast, 2017-2025
Table 6.1 SWOT Analysis for World Diabetes Market: Strengths & Weaknesses, 2010-2025
Table 6.2 SWOT Analysis for World Diabetes Market: Opportunities & Threats, 2010-2025
Table 6.3 Recent FDA Guidance on the Cardiovascular Risk of Diabetes Drugs
Table 7.1 Leading Diabetes Drugs: Country Markets, 2009
Table 7.2 Leading Anti-Diabetic Drugs: Country Market Sales Forecasts, 2010-2016
Table 7.3 Leading Anti-Diabetic Drugs: Country Market Sales Forecasts, 2017-2025
Table 8.1 Key Drugs in the Human Insulins and Analogues R&D Pipeline, 2009
Table 8.2 Key Drugs in the Glitazone Anti-Diabetics R&D Pipeline, 2009
Table 8.3 Key Drugs in the DPP-IV Inhibitor Anti-Diabetics R&D Pipeline, 2009
Table 8.4 Key Drugs in the Sulphonylurea and Biguanide Anti-Diabetics R&D Pipeline, 2009
Table 8.5 Key Drugs in the Alpha-Glucosidase Inhibitor Anti-Diabetics R&D Pipeline, 2009
Table 8.6 Key Drugs in the Miscellaneous Class R&D Pipeline, 2009

List of Figures
Figure 2.1 Rise in Diabetes Cases (in Millions), by WHO Region, 2000 & 2030
Figure 2.2 Secondary (Non-Medical) Costs of Diabetes in the US, 2007
Figure 2.3 Secondary Costs of Diabetes in Africa, 2007
Figure 3.1 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009
Figure 3.2 World Diabetes Pharmaceutical Market Sales Forecasts, 2010-2016
Figure 3.3 World Diabetes Pharmaceutical Market Sales Forecasts, 2017-2025
Figure 3.4 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2009
Figure 3.5 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2015
Figure 3.6 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2020
Figure 3.7 Diabetes Pharmaceutical Therapeutic Category Market Shares, 2025
Figure 3.8 Diabetes Pharmaceutical Therapeutic Category Sales Forecasts, 2010-2025
Figure 4.1 Lantus Sales Forecast, 2010-2025
Figure 4.2 Novorapid Sales Forecast, 2010-2025
Figure 4.3 Humalog Sales Forecast, 2010-2025
Figure 4.4 Novomix Sales Forecast, 2010-2025
Figure 4.5 Levemir Sales Forecast, 2010-2025
Figure 4.6 Actraphane HM Sales Forecast, 2010-2025
Figure 5.1 Actos HM Sales Forecast, 2010-2025
Figure 5.2 Avandia Sales Forecast, 2010-2025
Figure 5.3 Avandamet Sales Forecast, 2010-2025
Figure 5.4 Junuvia Sales Forecast, 2010-2025
Figure 5.5 Byetta Sales Forecast, 2010-2025
Figure 6.1 Global Population Aged Over 65 Years, 2010-2025
Figure 6.2 Population Aged 65 Years or Over in Major Anti-Diabetic Pharmaceutical Country Markets, 2009 and 2025
Figure 6.3 Prevalence of Diabetes Worldwide in Major Anti-Diabetic Pharmaceutical Country Markets, 2000 and 2030
Figure 6.4 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030
Figure 7.1 Leading Anti-Diabetic Drugs: Country Market Shares, 2009
Figure 7.2 Leading Anti-Diabetic Drugs: Country Market Shares, 2015
Figure 7.3 Leading Anti-Diabetic Drugs: Country Market Shares, 2020
Figure 7.4 Leading Anti-Diabetic Drugs: Country Market Shares, 2025
Figure 7.5 US and Japanese Anti-Diabetic Drugs: Market Sales Forecasts, 2010-2025
Figure 7.6 European, Chinese, Indian and Brazilian Anti-Diabetic Drugs: Market Sales Forecasts, 2010-2025 

Companies Listed

Abbott Laboratories Ltd.
Alkermes, Inc.
Altea Therapeutics Corp.
American Diabetes Association (ADA)
Amgen Inc.
Amylin Pharmaceuticals, Inc.
Andromeda Biotech (a subsidiary of Clal Biotechnology Industries)
Astellas Pharma Inc.
AstraZeneca plc.
Argyll Biotechnologies, LLC
Axcess Ltd.
Battelle Medical Device Solutions
Baxter International Inc.
Bayhill Therapeutics Inc.
Biocon Ltd.
Biodel Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Pharmaceuticals
BTG plc
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, US
Chiesi Ltd.
Chong Kun Dang Pharmaceutical Corp.
Choongwae Pharma Corp.
College of Pharmacy, Washington State University, WA, US
CPEX Pharmaceuticals, Inc.
DeveloGen AG
Diabetology Ltd.
Diamyd Medical AB
Diabetes and Obesity Research Center, Burnham Institute for Medical Research, La Jolla, CA, US
DPT Laboratories Ltd.
Dong Sung Industrial Co., Ltd.
Dr. Reddy's Laboratories Ltd.
Eli Lilly and Company Limited
European Medicines Agency (EMEA)
European Patent Convention
Emisphere Technologies, Inc.
Ergo Sciences Inc.
Forest Laboratories, Inc.
Flamel Technologies, Inc.
Food and Drug Administration (FDA) [US]
Garvan Institute of Medical Research, Sydney, Australia
Galenix Pharma and Galenix Inc.
Genentech Inc.
Generex Biotechnology Corp.
GlaxoSmithKline plc (GSK)
Glenmark Pharmaceuticals Ltd.
Human Genome Sciences, Inc.
Intarcia Therapeutics, Inc.
International Diabetes Federation (IDF)
Immunosyn Corporation
Ipsen Ltd.
Johnson & Johnson Inc.
Kissei Pharmaceutical Co, Ltd.
Kowa Company Ltd.
KYORIN Pharmaceutical Co., Ltd.
LG Life Sciences Ltd.
Lifescan UK (Ortho Clinical Diagnostics Ltd.)
MannKind Corp.
Merck & Co., Inc.
Metabolic Solutions Development Co.
Metabolex Inc.
Mitsubishi Tanabe Pharma Corp.
Nordic Bioscience A/S.
Novartis AG.
Novo Nordisk A/S.
Oramed Pharmaceuticals Inc.
Ortho-McNeil-Janssen Pharmaceuticals, Inc
PDL BioPharma Inc.
Pfizer Inc.
Phenomix Corp.
Phosphagenics Ltd.
Proxima Concepts Ltd.
Qdose Ltd.
Roche Holdings AG.
Royal Adelaide Hospital, Adelaide, Australia
S2 Therapeutics Inc.
Sanford Children's Health Research Center, La Jolla, California, US
Sanford Children's Health Research Center, La Jolla, California, US
Sanwa Kagaku Kenkyusho Co., Ltd.
SemBioSys Genetics Inc.
Servier Laboratories
Takeda Pharmaceuticals Co. Ltd.
Teijin Pharma Limited
Teva Pharmaceutical Industries Ltd.
Tolerance Therapeutics
Tolerx, Inc.
The National Diabetes Information Clearinghouse
University of California at Los Angeles (UCLA), US
University of Strathclyde, Glasgow, UK
VeroScience LLC.
Washington State University, WA, US
Watson Pharmaceuticals, Inc.
World Diabetes Congress of the International Diabetic Federation
World Health Organisation (WHO)
Yeda Research and Development Company Ltd.
Ypsomed Holding AG.
Zealand Pharma A/S 

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.